Literature DB >> 7776491

Diagnostic and therapeutic technology assessment. Transjugular intrahepatic portosystemic shunt (TIPS).

R Miller-Catchpole1.   

Abstract

OBJECTIVE: To provide clinicians with a technology assessment of the safety and effectiveness of the use of a transjugular intrahepatic portosystemic shunt (TIPS) for reducing portal hypertension and its associated complications of esophageal varices and ascites. PARTICIPANTS: A literature review and a Diagnostic and Therapeutic Technology Assessment (DATTA) survey questionnaire were mailed to 72 physicians with expertise in gastrointestinal or abdominal surgery or interventional radiology and a special interest in liver disease or esophageal varices. These panelists had been nominated to the DATTA panel by appropriate specialty societies and medical schools. A total of 54 panelists (75%) responded. EVIDENCE: Assessment was based on the expert opinion of the panelists, as well as on published scientific literature (available as of January 2, 1995). Published studies were identified by a MEDLINE search using the terms transjugular intrahepatic portosystemic shunt, TIPS, and transjugular and by review of the references cited in these primary sources. CONSENSUS PROCESS: The respondents completed a DATTA survey questionnaire; the survey results were tabulated, analyzed, and interpreted by an American Medical Association staff physician.
CONCLUSIONS: The safety of TIPS was considered to be established in the acute control of bleeding from esophageal varices in patients who had failed sclerotherapy. The safety of TIPS was considered to be promising for long-term control of bleeding from esophageal varices. In patients with end-stage liver disease and esophageal varices who are liver transplant candidates, the use of TIPS was considered to be an established therapy. The effectiveness of TIPS was considered to be (1) established in the acute control of bleeding in patients who failed sclerotherapy; (2) promising for long-term control of bleeding from esophageal varices; and (3) established in patients with end-stage liver disease and esophageal varices who are candidates for liver transplants.

Entities:  

Mesh:

Year:  1995        PMID: 7776491

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  4 in total

1.  Differential effects on portal and effective hepatic blood flow. A comparison between transjugular intrahepatic portasystemic shunt and small-diameter H-graft portacaval shunt.

Authors:  A S Rosemurgy; E E Zervos; S E Goode; T J Black; B R Zwiebel
Journal:  Ann Surg       Date:  1997-05       Impact factor: 12.969

2.  A prospective trial of transjugular intrahepatic portasystemic stent shunts versus small-diameter prosthetic H-graft portacaval shunts in the treatment of bleeding varices.

Authors:  A S Rosemurgy; S E Goode; B R Zwiebel; T J Black; P G Brady
Journal:  Ann Surg       Date:  1996-09       Impact factor: 12.969

3.  Balloon-occluded retrograde transvenous obliteration for gastric variceal bleeding: its feasibility compared with transjugular intrahepatic portosystemic shunt.

Authors:  Young Ho Choi; Chang Jin Yoon; Jae Hyung Park; Jin Wook Chung; Jong Won Kwon; Guk Myung Choi
Journal:  Korean J Radiol       Date:  2003 Apr-Jun       Impact factor: 3.500

4.  Emergency balloon-occluded retrograde transvenous obliteration of ruptured gastric varices.

Authors:  Tetsuo Sonomura; Wataru Ono; Morio Sato; Shinya Sahara; Kouhei Nakata; Hiroki Sanda; Nobuyuki Kawai; Hiroki Minamiguchi; Motoki Nakai; Kazushi Kishi
Journal:  World J Gastroenterol       Date:  2013-08-21       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.